Prevalence of hepatitis-C viral infection among opioid dependent injectable drug users: a study conducted at regional hospital drug de-addiction and treatment centre, Solan, Himachal Pradesh, India


  • Kushel Verma Medical Officer (Psychiatry), Regional Hospital, Solan, Himachal Pradesh, India
  • Sanjeev Kumar Medical Officer (Medicine), Regional Hospital, Solan, Himachal Pradesh, India
  • Vaishali Sharma Clinical Psycologist, Regional Hospital, Solan, Himachal Pradesh, India



Cannabis, Cocaine, Drug users, Intravenous drug user, Hepatitis B, Hepatitis C, Opioid-related disorders


Background: There are a limited number of studies regarding the prevalence of hepatitis B, hepatitis C and HIV infections among the drug addicts in Himachal Pradesh; C virus (HCV) infection in north India especially Himachal with very high rates of substance abuse. The present study was attempted to study the prevalence of hepatitis C among the injectable drug users, which is more important in a country like India where viral hepatitis is estimated to be among the top ten causes of deaths.

Methods: A study was conducted in 2019-2020 (July-April). HBsAg, anti-HBs, anti-HCV and anti-HIV tests in 235 drug addicts were studied. Urine samples obtained from drug addicts were analyzed for cannabis, opiate and cocaine metabolites.

Results: The subjects included were 235 IDUs who were opioid dependent. All the 235 drug users were males, and their mean age was 30.69±9.494 years; 112 (47.7%) of them were in the age group ranging 20 - 29 years (p <0.05). Of 235 drug addicts, 113 (48.1%) and 115 (48.9%) were only cannabis and opiate users, respectively. The frequencies of HBsAg, anti-HBs and anti-HCV among drug addicts were 2.6%, 38.3%, and 9.4%, respectively.

Conclusions: The obtained results showed that HCV infection was an alarming problem among opiate users in this part of Himachal. It is suggested to rapidly diagnose the infected persons; thus preventive measures and appropriate control may limit further transmission of these infections.


Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62.

Alter MJ. Hepatitis C virus infection in the United States. J Hepatol. 1999;31:88-91.

Hagan H, Des Jarlais DC. HIV and HCV infection amonginjecting drug users. Mt Sinai J Med. 2000;67:423-8.

Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of internal medicine. 2000 Feb 15;132(4):296-305.

Oliveira MLA, Bastos FI, Telles PR, Yoshida CFT, Schatzmayr HG, Paetzold U, et al. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Brazilian J Med Biol Res. 1999;32(9).

Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr. 2000;18(3):145-50.

McMahon JM, Simm M, Milano D, Clatts M. Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob. 2004;3:6.

Basu D. Overview of substance abuse and hepatitis C virus. Infection and Coinfections in India. J Neuroimmune Pharmacol. 2010;5:496-506.

Devi KS, Singh NB, Mara J, Singh TB, Singh YM. Seroprevalence of hepatitis B virus and hepatitis C virus among hepatic disorders and injecting drug users in Manipur - Apreliminary report. Indian J Med Microbiol. 2004;22:136-7.

Eicher AD, Crofts N, Benjamin S, Deutschmann P, Rodger AJ. A certain fate: spread of HIV among young injecting drug users in Manipur, north-east India. AIDS Care. 2000;12:497-504.

Chelleng PK, Borkakoty BJ, Chetia M, Das HK, Mahanta J. Risk of hepatitis C infection among injection drug users in Mizoram, India. Indian J Med Res. 2008;128:640-6.

Medina Mora ME. In support of substance use disorders. Addiction. 2011;106(5):887-8.

Keramat F, Eini P, Majzoobi MM. Seroprevalence of HIV, HBV and HCV in Persons Referred to Hamadan Behavioral Counseling Center, West of Iran. Iran Red Crescent Med J. 2011;13(1):42-6.

Pal D, Ojha SK. Prevalence of HIV and HCV amongst intravenous drug users of Kolkata. Indian J Med Microbiol. 2004;22:138.

Baveja UK, Chattopadhya D, Khera R, Joshi PM. A crosssectional serological study of the co-infection of hepatitis B virus,hepatitis C virus and human immunodeficiency virus amongst a cohort of idus at Delhi. Indian J Med Microbiol. 2003;21:280-3.

Sarkar K, Mitra S, Bal B, Charkraborty S, Bhattacharya SK. Rapid spread of hepatitis C and needle exchange programme in Kolkata, India. Lancet. 2003;361:1301-2.

Santana Rodriguez OE, Male Gil ML, HernandezSantana JF, Liminana Canal JM, Martin Sanchez AM. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol. 1998;14(6):555-61.

Removille N, Origer A, Couffignal S, Vaillant M, Schmit JC, Lair ML. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations. BMC Public Health. 2011;11:351.




How to Cite

Verma, K., Kumar, S., & Sharma, V. (2020). Prevalence of hepatitis-C viral infection among opioid dependent injectable drug users: a study conducted at regional hospital drug de-addiction and treatment centre, Solan, Himachal Pradesh, India. International Journal of Research in Medical Sciences, 8(7), 2458–2461.



Original Research Articles